NEW YORK, Dec. 14 /PRNewswire/ -- Pfizer Inc said today that the U.S.
District Court for the Southern District of New York has denied a motion
for a preliminary injunction that would have blocked further sales of its
inhalable insulin medication, Exubera(R), in the U.S. The preliminary
injunction was requested by Novo Nordisk as part of a patent infringement
case that will be heard by the same court.
Exubera is the only inhalable form of insulin to be approved by the
FDA. The court's decision allows the product to remain on the U.S. market,
and available to patients, while the case proceeds to trial.
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiveror electronic darkroom, PC or
Macintosh, that can accept overheadtransmissions. To retrieve a
logo, please call 972-392-0888.
http://www.prnewswire.com/comp/688250.html/ Pfizer's press
releases are available through PR Newswire's Company News On-Call
service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html/
CONTACT:
Bryant Haskins, +1-212-733-8719
|
